NCT00711620

Efficacy of Thymosin alpha1 for Severe Sepsis

Multicenter, Randomized, Controlled Study to Evaluate the Efficacy of Thymosin alpha1 in Patients With Severe Sepsis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 366 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.

Detailed description

Severe sepsis is a disease of infectious origin with a high risk of death. Over the past decade, thymosin alpha1 have already provided clinicians with additional weapon in the fight against infectious diseases, but it is unknown whether thymosin alpha1 is effective in treating severe sepsis.

Conditions

• Severe Sepsis

Interventions

Type	Name	Description
DRUG	Thymosin alpha 1	1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.

Timeline

• Start date: 2008-05-01
• Primary completion: 2010-12-01
• Completion: 2011-01-01
• First posted: 2008-07-09
• Last updated: 2011-06-14

Locations

1 site across 1 country: China